**Supplementary Table S1: Sample collection used in these evaluations**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Preliminary evaluation  sera | | Complete evaluation  sera | | Total |
| **Sera** | **negative** | **positive** | **negative** | **positive** |  |
| Anterior (B19) |  |  | 14 |  | 14 |
| Anterior (CMV) |  |  | 33 |  | 33 |
| Anterior (EBV) |  |  | 22 |  | 22 |
| Anterior (TBEV) |  |  | 13 |  | 13 |
| Anterior (Hcov) | 18 |  |  |  | 18 |
| Anterior (HSV1) |  |  | 14 |  | 14 |
| Anterior (HSV1-2) |  |  | 3 |  | 3 |
| Anterior (HSV2) |  |  | 4 |  | 4 |
| Anterior (Influ A) |  |  | 28 |  | 28 |
| Anterior (Influ A/B) |  |  | 2 |  | 2 |
| Anterior (Influ A/RSV) |  |  | 2 |  | 2 |
| Anterior (Influ B) |  |  | 10 |  | 10 |
| Anterior (Influ B/RSV) |  |  | 1 |  | 1 |
| Anterior (non-specific) | 39 |  | 90 |  | 129 |
| Anterior (mumps) |  |  | 11 |  | 11 |
| Anterior (measles) |  |  | 13 |  | 13 |
| Anterior (measles-mumps) |  |  | 3 |  | 3 |
| Anterior (RSV) |  |  | 18 |  | 18 |
| Anterior (Rub) |  |  | 17 |  | 17 |
| Anterior (VZV) |  |  | 11 |  | 11 |
| Anterior (anti-PR3) |  |  | 1 |  | 1 |
| Anterior (anti-PR4) |  |  | 1 |  | 1 |
| Anterior (anti-SCL70) |  |  | 1 |  | 1 |
| Anterior (anti-SCL71) |  |  | 1 |  | 1 |
| Anterior (FR) |  |  | 1 |  | 1 |
| Anterior (FR+anti-CCP) |  |  | 2 |  | 2 |
| Anterior (HAV) |  |  | 2 |  | 2 |
| Anterior (HBV) |  |  | 2 |  | 2 |
| Anterior (HCV) |  |  | 2 |  | 2 |
| Anterior (HDV+HBV) |  |  | 1 |  | 1 |
| Anterior (HDV+HBV+HCV) |  |  | 1 |  | 1 |
| Anterior (HEV) |  |  | 2 |  | 2 |
| Anterior (HIV) |  |  | 7 |  | 7 |
| Anterior (Lupus) | 12 |  |  |  | 12 |
| Anterior (Tocilizumab) |  |  | 2 |  | 2 |
| COVID-19 (positive RT-PCR) |  | 113 |  | 65 | 178 |
| **Total** | **69** | **113** | **335** | **65** | **582** |

“Anterior” sera were sampled before 1 November 2019, between brackets is indicated the micro-organism for which they were known to be positive : Herpes simplex virus 1 and 2 (HSV1, HSV2), Respiratory Syncytial Virus (RSV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), mumps virus (mumps), Measles virus (measles), Parvovirus B19 (B19), rubella virus (rub), Tick-borne encephalitis virus (TBEV), Influenza A and B, (Influ A and Influ B), Varicella-Zoster virus (VZV), Human Immunodeficiency virus (HIV), Hepatitis virus A, B, C, D, and E (HAV, HBV, HCV, HDV, HEV), and some rheumatoid factors (FR), or auto-antibodies (anti-PR3, -PR4, -SCL70, -SCL71, -CCP)**.**

**Supplementary Table S2: Characteristics of the serologic tests evaluated in this study**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Manufacturer** | **Name of the test** | **Reference of manufacturer** | **Production Country** | **Type of Test** | **Certification** | **Target** | **Sample type** |
| Epitope diagnostic | *EDI™* Novel Coronavirus COVID-19 IgG ELISA Kit | KT-1032 | USA | ELISA IgG | CE - IVD | N Protein | Human serum or EDTA, heparin or citrate plasma |
| *EDI™* Novel Coronavirus COVID-19 IgM ELISA Kit | KT-1033 | ELISA IgM |
| Euroimmun | Anti-SARS-CoV-2 ELISA (IgG) | EI 2606-9601 G | DE | ELISA IgG | CE - IVD | S1 Peptide | Human serum or EDTA, heparin or citrate plasma |
| Anti-SARS-CoV-2 ELISA (IgA) | EI 2606-9601 A | ELISA IgA |
| ImmunoDiagnostics limited | SARS-CoV-2 NP IgG ELISA Kit | 41A222 | China (Hong-Kong) | ELISA IgG | CE - IVD | N protein | Serum or plasma |
| SARS-CoV-2 NP IgM ELISA kit | 41A224 | ELISA IgM |
| Vircell | COVID-19 ELISA IgG | G1032 | SP | ELISA IgG | CE - IVD | N and S proteins | Serum or plasma |
| COVID-19 ELISA IgM+IgA | MA1032 | ELISA IgM+IgA |
| Creative diagnostic | SARS-CoV-2 IgG ELISA Kit | DEIASL019 | USA | ELISA IgG | RUO | Whole virus lysate | serum or plasma |
| SARS-CoV-2 IgM ELISA Kit | DEIASL020 | ELISA IgM | N and S proteins | serum or plasma |
| Dynamiker | 2019-nCOV IgG/IgM Rapid Test | DNK-1419-1 | China | LFA IgG/IgM | CE - IVD | N protein | serum or plasma |
| Nal Von Minden | NADAL® COVID-19 IgG/IgM Test | 243003N-20 | DE | LFA IgG/IgM | CE - IVD | S protein | serum, plasma, fingertip blood or whole blood samples |
| Augurix diagnostic | One Step Test for  Novel Coronavirus (2019-nCoV) IgM/IgG Antibody | CG2057 | CH / China | LFA IgG/IgM | CE - IVD | N and S proteins | serum, plasma, fingertip blood or whole blood samples |
| Diasorin | ISON® SARS-CoV-2 IgG kit | 311450 | IT | C IgG |  | S1, S2 protein domains | Serum or plasma |
| Snibe | MAGLUMITM 2019-nCoV IgG (C) | 130219015M | China | C IgG | CE - IVD | N and S proteins | Serum or plasma |
| MAGLUMITM 2019-nCoV IgM (C) | 130219016M | China | C IgM |
| Roche | Elecsys anti-SARS-CoV-2 | 09203095190 | DE | EC Ig total | CE - IVD | N protein | Human serum or EDTA, heparin plasma |

CE: European conformity, IVD: In Vitro Diagnostic Medical Device ; USA: United States of America, DE : Germany, SP: Spain, CH : Switzerland, IT: Italy. ELISA : enzyme-linked immunosorbent assay ; LFIA : lateral flow immuno-assay ; CLIA : chemi-luminescence immuno-assay ; ECLIA : electro chemi-luminescence immune-assay

**Supplementary Table S3.** Preliminary evaluation: Performance of sensitivity and specificity of the ELISA tests

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Test** | **Days post-symptoms** | **N° Total IgG** | **N° pos** | **N° neg** | **IgG Se** | **IgG Se 95% CI** | **IgG Sp** | **IgG Sp 95% CI** | **N° Total IgM/IgA** | **N° pos** | **N° neg** | **IgM/IgA Se** | **IgM/IgA Se 95% CI** | **IgM/IgA Sp** | **IgM/IgA Sp 95% CI** |
| **ELISA Epitope Dx** | All\* | 175 | 110 | 65 | 0.75 | 0.67 to 0.83 | 0.98 | 0.92 to 1.0 | 165 | 101 | 64 | 0.42 | 0.32 to 0.51 | 1 | 0.94 to 1.0 |
|  | 0-5 | 72 | 7 | 65 | 0.14 | 0.0073 to 0.51 | 0.98 | 0.92 to 1.0 | 72 | 8 | 64 | 0 | 0.0 to 0.32 | 1 | 0.94 to 1.0 |
|  | 6-10 | 83 | 18 | 65 | 0.44 | 0.25 to 0.66 | 0.98 | 0.92 to 1.0 | 82 | 18 | 64 | 0.11 | 0.020 to 0.33 | 1 | 0.94 to 1.0 |
|  | 11-15 | 101 | 36 | 65 | 0.89 | 0.75 to 0.96 | 0.98 | 0.92 to 1.0 | 96 | 32 | 64 | 0.53 | 0.36 to 0.69 | 1 | 0.94 to 1.0 |
|  | **>15** | **97** | **32** | **65** | **0.91** | **0.76 to 0.97** | **0.98** | **0.92 to 1.0** | **92** | **28** | **64** | **0.64** | **0.46 to 0.79** | **1** | **0.94 to 1.0** |
| **ELISA Euroimmun** | All\* | 173 | 105 | 68 | 0.67 | 0.57 to 0.75 | 0.97 | 0.90 to 0.99 | 169 | 105 | 64 | 0.8 | 0.71 to 0.87 | 0.88 | 0.77 to 0.94 |
|  | 0-5 | 76 | 8 | 68 | 0.13 | 0.0064 to 0.47 | 0.97 | 0.90 to 0.99 | 72 | 8 | 64 | 0.25 | 0.044 to 0.59 | 0.88 | 0.77 to 0.94 |
|  | 6-10 | 86 | 18 | 68 | 0.28 | 0.12 to 0.51 | 0.97 | 0.90 to 0.99 | 83 | 19 | 64 | 0.58 | 0.36 to 0.77 | 0.88 | 0.77 to 0.94 |
|  | 11-15 | 102 | 34 | 68 | 0.79 | 0.63 to 0.90 | 0.97 | 0.90 to 0.99 | 99 | 35 | 64 | 0.91 | 0.78 to 0.97 | 0.88 | 0.77 to 0.94 |
|  | **>15** | **100** | **32** | **68** | **0.88** | **0.72 to 0.95** | **0.97** | **0.90 to 0.99** | **95** | **31** | **64** | **0.9** | **0.75 to 0.97** | **0.88** | **0.77 to 0.94** |
| **ELISA Vircell** | All\* | 174 | 110 | 64 | 0.74 | 0.65 to 0.81 | 0.97 | 0.89 to 0.99 | 162 | 106 | 56 | 0.91 | 0.83 to 0.95 | 0.46 | 0.34 to 0.59 |
|  | 0-5 | 72 | 8 | 64 | 0.13 | 0.0064 to 0.47 | 0.97 | 0.89 to 0.99 | 63 | 7 | 56 | 0.29 | 0.051 to 0.64 | 0.46 | 0.34 to 0.59 |
|  | 6-10 | 83 | 19 | 64 | 0.47 | 0.27 to 0.68 | 0.97 | 0.89 to 0.99 | 72 | 16 | 56 | 0.81 | 0.57 to 0.93 | 0.46 | 0.34 to 0.59 |
|  | 11-15 | 100 | 36 | 64 | 0.83 | 0.68 to 0.92 | 0.97 | 0.89 to 0.99 | 92 | 36 | 56 | 1 | 0.90 to 1.0 | 0.46 | 0.34 to 0.59 |
|  | **>15** | **108** | **44** | **64** | **0.93** | **0.82 to 0.98** | **0.97** | **0.89 to 0.99** | **100** | **44** | **56** | **0.98** | **0.88 to 1.0** | **0.46** | **0.34 to 0.59** |
| **ELISA Creative Dx** | All\* | 182 | 113 | 69 | 0.65 | 0.55 to 0.73 | 0.99 | 0.92 to 1.0 | 182 | 113 | 69 | 0.83 | 0.75 to 0.89 | 0.36 | 0.26 to 0.48 |
|  | 0-5 | 77 | 8 | 69 | 0 | 0.0 to 0.32 | 0.99 | 0.92 to 1.0 | 77 | 8 | 69 | 0.13 | 0.0064 to 0.47 | 0.36 | 0.26 to 0.48 |
|  | 5-10 | 88 | 19 | 69 | 0.32 | 0.15 to 0.54 | 0.99 | 0.92 to 1.0 | 88 | 19 | 69 | 0.63 | 0.41 to 0.81 | 0.36 | 0.26 to 0.48 |
|  | 10-15 | 107 | 38 | 69 | 0.71 | 0.55 to 0.83 | 0.99 | 0.92 to 1.0 | 107 | 38 | 69 | 0.97 | 0.87 to 1.0 | 0.36 | 0.26 to 0.48 |
|  | **>15** | **110** | **41** | **69** | **0.93** | **0.81 to 0.97** | **0.99** | **0.92 to 1.0** | **110** | **41** | **69** | **0.93** | **0.81 to 0.97** | **0.36** | **0.26 to 0.48** |
| **ELISA Immuno Dx** | All\* | 180 | 114 | 66 | 0.76 | 0.68 to 0.83 | 0.48 | 0.37 to 0.60 | 182 | 115 | 67 | 0.79 | 0.71 to 0.86 | 0.7 | 0.58 to 0.80 |
|  | 0-5 | 74 | 8 | 66 | 0 | 0.0 to 0.32 | 0.48 | 0.37 to 0.60 | 75 | 8 | 67 | 0.13 | 0.0064 to 0.47 | 0.7 | 0.58 to 0.80 |
|  | 6-10 | 85 | 19 | 66 | 0.58 | 0.36 to 0.77 | 0.48 | 0.37 to 0.60 | 86 | 19 | 67 | 0.53 | 0.32 to 0.73 | 0.7 | 0.58 to 0.80 |
|  | 11-15 | 104 | 38 | 66 | 0.82 | 0.67 to 0.91 | 0.48 | 0.37 to 0.60 | 105 | 38 | 67 | 0.89 | 0.76 to 0.96 | 0.7 | 0.58 to 0.80 |
|  | **>15** | **112** | **46** | **66** | **0.96** | **0.85 to 0.99** | **0.48** | **0.37 to 0.60** | **113** | **46** | **67** | **0.93** | **0.82 to 0.98** | **0.7** | * 1. **o 0.80** |

\*: Numbers indicated in the “All” row contain the results of RT-PCR positive patients for who no beginning of symptoms date could be defined. De facto, those data are not taken in consideration in the following rows. The difference between the “N° Total IgG or IgM/IgA” with 182 tested sera, correspond to the “indetermined” results, which can be attributed to neither positive (pos) nor negative (neg) ones. †: For each row, the “N° Total IgG or IgM/IgA” contains the number of negative sera, which are the same for all the different categories, plus the number of the positive ones for a given row. Therefore the sum of the “N° Total IgG or IgM” rows does not correspond to the “All” one. Se : sensitivity ; Sp : Specificity

**Supplementary Table S4**. Preliminary evaluation: Performance of sensitivity and specificity of the LFA tests

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Test** | **Days post-symptoms** | **N° Total IgG** | **N° pos** | **N° nég** | **IgG Se** | **IgG Se 95% CI** | **IgG Sp** | **IgG Sp 95% CI** | **N° Total IgM** | **N° pos** | **N° nég** | **IgM Se** | **IgM Se 95% CI** | **IgM Sp** | **IgM Sp 95% CI** |
| **LFA Dynamiker** | All\* | 180 | 111 | 69 | 0.66 | 0.57 to 0.74 | 0.99 | 0.92 to 1.0 | 177 | 108 | 69 | 0.7 | 0.61 to 0.78 | 0.93 | 0.84 to 0.97 |
|  | 0-5 | 77 | 8 | 69 | 0 | 0.0 to 0.32 | 0.99 | 0.92 to 1.0 | 76 | 7 | 69 | 0 | 0.0 to 0.35 | 0.93 | 0.84 to 0.97 |
|  | 6-10 | 87 | 18 | 69 | 0.33 | 0.16 to 0.56 | 0.99 | 0.92 to 1.0 | 87 | 18 | 69 | 0.39 | 0.20 to 0.61 | 0.93 | 0.84 to 0.97 |
|  | 11-15 | 106 | 37 | 69 | 0.7 | 0.54 to 0.83 | 0.99 | 0.92 to 1.0 | 105 | 36 | 69 | 0.78 | 0.62 to 0.88 | 0.93 | 0.84 to 0.97 |
|  | **>15** | **101** | **32** | **69** | **0.91** | **0.76 to 0.97** | **0.99** | **0.92 to 1.0** | **100** | **31** | **69** | **0.94** | **0.79 to 0.99** | **0.93** | **0.84 to 0.97** |
| **LFA NADAL** | All\* | 175 | 107 | 68 | 0.64 | 0.55 to 0.73 | 1 | 0.95 to 1.0 | 173 | 106 | 67 | 0.75 | 0.65 to 0.82 | 0.99 | 0.92 to 1.0 |
|  | 0-5 | 75 | 7 | 68 | 0 | 0.0 to 0.35 | 1 | 0.95 to 1.0 | 74 | 7 | 67 | 0 | 0.0 to 0.35 | 0.99 | 0.92 to 1.0 |
|  | 6-10 | 86 | 18 | 68 | 0.33 | 0.16 to 0.56 | 1 | 0.95 to 1.0 | 84 | 17 | 67 | 0.41 | 0.22 to 0.64 | 0.99 | 0.92 to 1.0 |
|  | 11-15 | 103 | 35 | 68 | 0.77 | 0.61 to 0.88 | 1 | 0.95 to 1.0 | 102 | 35 | 67 | 0.86 | 0.71 to 0.94 | 0.99 | 0.92 to 1.0 |
|  | **>15** | **99** | **31** | **68** | **0.84** | **0.67 to 0.93** | **1** | **0.95 to 1.0** | **99** | **32** | **67** | **0.94** | **0.80 to 0.99** | **0.99** | **0.92 to 1.0** |
| **LFA Augurix** | All\* | 172 | 105 | 67 | 0.67 | 0.57 to 0.75 | 1 | 0.95 to 1.0 | 163 | 95 | 68 | 0.095 | 0.051 to 0.17 | 1 | 0.95 to 1.0 |
|  | 0-5 | 75 | 8 | 67 | 0 | 0.0 to 0.32 | 1 | 0.95 to 1.0 | 76 | 8 | 68 | 0 | 0.0 to 0.32 | 1 | 0.95 to 1.0 |
|  | 6-10 | 85 | 18 | 67 | 0.22 | 0.090 to 0.45 | 1 | 0.95 to 1.0 | 86 | 18 | 68 | 0.11 | 0.020 to 0.33 | 1 | 0.95 to 1.0 |
|  | 11-15 | 99 | 32 | 67 | 0.75 | 0.58 to 0.87 | 1 | 0.95 to 1.0 | 101 | 33 | 68 | 0.03 | 0.0016 to 0.15 | 1 | 0.95 to 1.0 |
|  | **>15** | **111** | **44** | **67** | **0.93** | **0.82 to 0.98** | **1** | **0.95 to 1.0** | **101** | **33** | **68** | **0.18** | **0.086 to 0.34** | **1** | **0.95 to 1.0** |

\*: Numbers indicated in the “All” row contain the results of RT-PCR positive patients for who no beginning of symptoms date could be defined. De facto, those data are not taken in consideration in the following rows. The difference between the “N° Total IgG or IgM/IgA” with 182 tested sera, correspond to the “indetermined” results, which can be attributed to neither positive (pos) nor negative (neg) ones. †: For each row, the “N° Total IgG or IgM/IgA” contains the number of negative sera, which are the same for all the different categories, plus the number of the positive ones for a given row. Therefore the sum of the “N° Total IgG or IgM” rows does not correspond to the “All” one. Se : sensitivity ; Sp : Specificity

**Supplementary Table S5**. Preliminary evaluation: Performance of sensitivity and specificity of the CLIA tests

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Test** | **Days post-symptoms** | **N° Total IgG/Ig** | **N° pos** | **N° nég** | **IgG/Ig Se** | **IgG/Ig Se 95% CI** | **IgG/Ig Sp** | **IgG/Ig Sp 95% CI** | **N° Total IgM** | **N° pos** | **N° nég** | **IgM Se** | **IgM Se 95% CI** | **IgM Sp** | **IgM Sp 95% CI** |
| **CLIA Diasorin** | All\* | 174 | 107 | 67 | 0.53 | 0.44 to 0.62 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 0-5 | 75 | 8 | 67 | 0 | 0.0 to 0.32 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 6-10 | 86 | 19 | 67 | 0.21 | 0.085 to 0.43 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 11-15 | 104 | 37 | 67 | 0.57 | 0.41 to 0.71 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | **>15** | **97** | **30** | **67** | **0.83** | **0.66 to 0.93** | **1** | **0.95 to 1.0** | ND | ND | ND | ND | ND | ND | ND |
| **CLIA Snibe** | All\* | 175 | 107 | 68 | 0.64 | 0.54 to 0.72 | 1 | 0.95 to 1.0 | 175 | 108 | 67 | 0.6 | 0.51 to 0.69 | 0.99 | 0.92 to 1.0 |
|  | 0-5 | 76 | 8 | 68 | 0 | 0.0 to 0.32 | 1 | 0.95 to 1.0 | 75 | 8 | 67 | 0 | 0.0 to 0.32 | 0.99 | 0.92 to 1.0 |
|  | 6-10 | 87 | 19 | 68 | 0.32 | 0.15 to 0.54 | 1 | 0.95 to 1.0 | 86 | 19 | 67 | 0.37 | 0.19 to 0.59 | 0.99 | 0.92 to 1.0 |
|  | 11-15 | 105 | 37 | 68 | 0.73 | 0.57 to 0.85 | 1 | 0.95 to 1.0 | 104 | 37 | 67 | 0.76 | 0.60 to 0.87 | 0.99 | 0.92 to 1.0 |
|  | **>15** | **98** | **30** | **68** | **0.9** | **0.74 to 0.97** | **1** | **0.95 to 1.0** | **97** | **30** | **67** | **0.8** | **0.63 to 0.90** | **0.99** | **0.92 to 1.0** |
| **CLIA Roche** | All\* | 174 | 107 | 67 | 0.73 | 0.64 to 0.80 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 0-5 | 75 | 8 | 67 | 0 | 0.0 to 0.32 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 6-10 | 86 | 19 | 67 | 0.47 | 0.27 to 0.68 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 11-15 | 104 | 37 | 67 | 0.86 | 0.72 to 0.94 | 1 | 0.95 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | **>15** | **97** | **30** | **67** | **0.93** | **0.79 to 0.99** | **1** | **0.95 to 1.0** | ND | ND | ND | ND | ND | ND | ND |

\*: Numbers indicated in the “All” row contain the results of RT-PCR positive patients for who no beginning of symptoms date could be defined. De facto, those data are not taken in consideration in the following rows. The difference between the “N° Total IgG or IgM/IgA” with 182 tested sera, correspond to the “indetermined” results, which can be attributed to neither positive (pos) nor negative (neg) ones. †: For each row, the “N° Total IgG or IgM/IgA” contains the number of negative sera, which are the same for all the different categories, plus the number of the positive ones for a given row. Therefore the sum of the “N° Total IgG or IgM” rows does not correspond to the “All” one. Se : sensitivity ; Sp : Specificity

**Supplementary Table S6**. Complete evaluation: Performance of sensitivity and specificity of the ELISA Epitope Dx IgG, LFA Dynamiker IgG/IgM, CLIA Snibe IgG/IgM and CLIA Diasorin IgG.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Test** | **Days post-symptoms** | **N° Total IgG** | **N° pos** | **N° nég** | **IgG Se** | **IgG Se 95% CI** | **IgG Sp** | **IgG Sp 95% CI** | **N° Total IgM** | **N° pos** | **N° nég** | **IgM Se** | **IgM Se 95% CI** | **IgM Sp** | **IgM Sp 95% CI** |
| **ELISA Epitope Dx** | All\*† | 569 | 178 | 391 | 0.82 | 0.76 to 0.87 | 0.98 | 0.97 to 0.99 | ND | ND | ND | ND | ND | ND | ND |
|  | 0-5 | 402 | 11 | 391 | 0.18 | 0.032 to 0.48 | 0.98 | 0.97 to 0.99 | ND | ND | ND | ND | ND | ND | ND |
|  | 6-10 | 419 | 28 | 391 | 0.57 | 0.39 to 0.73 | 0.98 | 0.97 to 0.99 | ND | ND | ND | ND | ND | ND | ND |
|  | 11-15 | 438 | 47 | 391 | 0.91 | 0.80 to 0.97 | 0.98 | 0.97 to 0.99 | ND | ND | ND | ND | ND | ND | ND |
|  | **>15** | **466** | **75** | **391** | **0.96** | **0.89 to 0.99** | **0.98** | **0.97 to 0.99** | ND | ND | ND | ND | ND | ND | ND |
| **LFA Dynamiker** | All\* | 582 | 179 | 403 | 0.75 | 0.68 to 0.81 | 0.98 | 0.95 to 0.99 | 577 | 176 | 401 | 0.79 | 0.72 to 0.84 | 0.96 | 0.94 to 0.98 |
|  | 0-5 | 415 | 12 | 403 | 0.083 | 0.0043 to 0.35 | 0.98 | 0.95 to 0.99 | 412 | 11 | 401 | 0.18 | 0.032 to 0.48 | 0.96 | 0.94 to 0.98 |
|  | 6-10 | 431 | 28 | 403 | 0.43 | 0.27 to 0.61 | 0.98 | 0.95 to 0.99 | 429 | 28 | 401 | 0.5 | 0.33 to 0.67 | 0.96 | 0.94 to 0.98 |
|  | 11-15 | 451 | 48 | 403 | 0.77 | 0.63 to 0.87 | 0.98 | 0.95 to 0.99 | 448 | 47 | 401 | 0.83 | 0.70 to 0.91 | 0.96 | 0.94 to 0.98 |
|  | **>15** | **478** | **75** | **403** | **0.96** | **0.89 to 0.99** | **0.98** | **0.95 to 0.99** | **475** | **74** | **401** | **0.97** | **0.91 to 1.0** | **0.96** | **0.94 to 0.98** |
| **CLIA Snibe** | All\* | 579 | 176 | 403 | 0.73 | 0.66 to 0.79 | 0.99 | 0.97 to 0.99 | 579 | 177 | 402 | 0.71 | 0.64 to 0.77 | 0.98 | 0.96 to 0.99 |
|  | 0-5 | 415 | 12 | 403 | 0 | 0.0 to 0.24 | 0.99 | 0.97 to 0.99 | 414 | 12 | 402 | 0.083 | 0.0043 to 0.35 | 0.98 | 0.96 to 0.99 |
|  | 6-10 | 432 | 29 | 403 | 0.41 | 0.26 to 0.59 | 0.99 | 0.97 to 0.99 | 431 | 29 | 402 | 0.45 | 0.28 to 0.62 | 0.98 | 0.96 to 0.99 |
|  | 11-15 | 451 | 48 | 403 | 0.79 | 0.66 to 0.88 | 0.99 | 0.97 to 0.99 | 450 | 48 | 402 | 0.81 | 0.68 to 0.90 | 0.98 | 0.96 to 0.99 |
|  | **>15** | **477** | **74** | **403** | **0.96** | **0.89 to 0.99** | **0.99** | **0.97 to 0.99** | **476** | **74** | **402** | **0.91** | **0.82 to 0.95** | **0.98** | **0.96 to 0.99** |
| **CLIA Diasorin** | All\* | 584 | 175 | 409 | 0.65 | 0.58 to 0.72 | 1 | 0.99 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 0-5 | 421 | 12 | 409 | 0 | 0.0 to 0.24 | 1 | 0.99 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 6-10 | 437 | 28 | 409 | 0.32 | 0.18 to 0.51 | 1 | 0.99 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | 11-15 | 457 | 48 | 409 | 0.63 | 0.48 to 0.75 | 1 | 0.99 to 1.0 | ND | ND | ND | ND | ND | ND | ND |
|  | **>15** | **483** | **74** | **409** | **0.92** | **0.83 to 0.96** | **1** | **0.99 to 1.0** | ND | ND | ND | ND | ND | ND | ND |

\*: Numbers indicated in the “All” row contain the results of RT-PCR positive patients for who no beginning of symptoms date could be defined. De facto, those data are not taken in consideration in the following rows. The difference between the “N° Total IgG or IgM/IgA” with 182 tested sera, correspond to the “indetermined” results, which can be attributed to neither positive (pos) nor negative (neg) ones. †: For each row, the “N° Total IgG or IgM/IgA” contains the number of negative sera, which are the same for all the different categories, plus the number of the positive ones for a given row. Therefore the sum of the “N° Total IgG or IgM” rows does not correspond to the “All” one. Se : sensitivity ; Sp : Specificity